Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Holding CSTL?
Track your performance easily
CSTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.97 - $35.84
Previous CloseN/A
Volume108.23K
Average Volume (3M)402.16K
Market Cap
$702.70M
Enterprise Value$585.47M
Total Cash (Recent Filing)$1.21M
Total Debt (Recent Filing)$17.60M
Price to Earnings (P/E)124.8
Beta0.85
Next Earnings
Mar 04, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding28,007,301
10 Day Avg. Volume632,456
30 Day Avg. Volume402,159
Standard Deviation0.16
R-Squared0.09
Alpha-0.00003
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.25
Price to Cash Flow (P/CF)7.50
P/FCF Ratio10.30
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda23.36
Forecast
1Y Price Target
$40.17Price Target Upside61.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Castle Biosciences News
PremiumCompany Announcements
Castle Biosciences Projects Strong Revenue Growth for 2024
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCSTL delivered another strong beat and raise and delivered its second consecutive quarter of GAAP profit.
Growth OpportunitiesStrong long-term growth opportunities are seen, both organic and through acquisition, as the company strengthens its core dermatology business and leverages newer verticals.
Market PotentialThe TissueCypher test is highlighted in practice guidelines and has a large market opportunity with only 5.5% penetration, indicating significant growth potential.
Bears Say
Coverage RemovalNovitas finalized its 'Genetic Testing in Oncology: Specific Tests' LCD, removing coverage for Dx-SCC as of February 23, taking Dx-SCC off the table for an indefinite period.
Financial ImpactRunning non-paid tests will be detrimental to gross margins, despite Dx-SCC being broadly adopted by the dermatology community.
Uncertain FutureFuture coverage for DDx-SCC remains uncertain as Palmetto continues to noncover the test, and Novitas' decision on oncology LCD is pending.
---
Ownership Overview
2.83% Insiders
27.83% Mutual Funds
0.55% Other Institutional Investors
54.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $16.96 and its highest was $35.84 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $702.70M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Nov 04, 2024. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.084.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is 0.03.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 28,007,301 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went down -7.402%.
Which hedge fund is a major shareholder of Castle Biosciences?
Among the largest hedge funds holding Castle Biosciences’s share is Deerfield Management Company, LP. It holds Castle Biosciences’s shares valued at 483K.
---
Castle Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.17 (61.07% Upside)
$40.17 (61.07% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 853.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.69%
12-Months-Change
Fundamentals
Return on Equity
1.47%
Trailing 12-Months
Asset Growth
18.01%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
---
CSTL Company Deck
---
CSTL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Castle Biosciences reported strong financial performance with significant revenue and test volume growth across its portfolio. The company achieved positive cash flow and raised its revenue guidance for 2024. However, challenges regarding reimbursement, potential impact from recent hurricanes, and ongoing efforts to secure coverage for certain tests were noted.Read More>---
CSTL Stock 12 Month Forecast
Average Price Target
$40.17
▲(61.07% Upside)
Technical Analysis
Exact Sciences
―
Guardant Health
―
Natera
―
Fulgent Genetics
―
Myriad Genetics
―
Sarepta Therapeutics
―
Best Analysts Covering CSTL
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+15.46%
reiterated a buy rating 6 days ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.46% per trade.
---